Japan is expected to record the highest number, with 1.06 million cases at that time.
GlobalData said the general total of chronic hepatitis B (CHB) in seven major markets (7mm) is expected to increase at an annual growth rate (AGR) from nearly 3.89 million in 2024 to 3.89 million in 2034.
In contrast, the number of CHB diagnosed cases is expected to decrease -0.13% to 2.06 million from 2.09 million in the period.
Although extensive vaccination and prevention efforts have reduced prevalence of the disease, expanded testing and case findings have increased diagnosis.
“Although it can be prevented by a widely available vaccine, CHB remains a public health issue of 7mm due to insufficient screening and treatment coverage,” said Molly Moran, senior epidemiologist at GlobalData.
Japan is expected to have the largest number of total epidemic cases in 7mm, with about 1.06 million cases, while Spain is expected to have about 286,000 cases.
“Continuing to focus on preventing initial infections and investment, especially in children, will result in fewer CHB cases requiring lifetime care,” Moran added.
7mm = us, France, Germany, Italy, Spain, Britain and Japan.
